Inhibrx, Inc. (INBX)
NASDAQ: INBX · IEX Real-Time Price · USD
34.14
-0.05 (-0.15%)
At close: May 24, 2024, 4:00 PM
35.00
+0.86 (2.52%)
After-hours: May 24, 2024, 4:48 PM EDT

Inhibrx Statistics

Total Valuation

Inhibrx has a market cap or net worth of $1.79 billion. The enterprise value is $1.75 billion.

Market Cap 1.79B
Enterprise Value 1.75B

Important Dates

The next estimated earnings date is Tuesday, June 4, 2024, after market close.

Earnings Date Jun 4, 2024
Ex-Dividend Date n/a

Share Statistics

Inhibrx has 52.40 million shares outstanding. The number of shares has increased by 25.20% in one year.

Shares Outstanding 52.40M
Shares Change (YoY) +25.20%
Shares Change (QoQ) +0.82%
Owned by Insiders (%) 17.70%
Owned by Institutions (%) 73.77%
Float 29.09M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 1,003.37
Forward PS n/a
PB Ratio 154.65
P/FCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 980.04
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 3.82, with a Debt / Equity ratio of 18.23.

Current Ratio 3.82
Quick Ratio 3.56
Debt / Equity 18.23
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -7.37

Financial Efficiency

Return on equity (ROE) is -678.50% and return on invested capital (ROIC) is -112.06%.

Return on Equity (ROE) -678.50%
Return on Assets (ROA) -91.70%
Return on Capital (ROIC) -112.06%
Revenue Per Employee $10,366
Profits Per Employee -$1.58M
Employee Count 172
Asset Turnover 0.01
Inventory Turnover n/a

Taxes

In the past 12 months, Inhibrx has paid $3,000 in taxes.

Income Tax 3,000
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +46.15% in the last 52 weeks. The beta is 2.88, so Inhibrx's price volatility has been higher than the market average.

Beta (1Y) 2.88
52-Week Price Change +46.15%
50-Day Moving Average 34.57
200-Day Moving Average 28.26
Relative Strength Index (RSI) 44.16
Average Volume (30 Days) 540,236

Short Selling Information

The latest short interest is 2.05 million, so 3.92% of the outstanding shares have been sold short.

Short Interest 2.05M
Short Previous Month 2.19M
Short % of Shares Out 3.92%
Short % of Float 7.06%
Short Ratio (days to cover) 5.78

Income Statement

In the last 12 months, Inhibrx had revenue of $1.78 million and -$271.16 million in losses. Loss per share was -$5.44.

Revenue 1.78M
Gross Profit 1.78M
Operating Income -249.28M
Pretax Income -271.15M
Net Income -271.16M
EBITDA -235.69M
EBIT -238.75M
Loss Per Share -$5.44
Full Income Statement

Balance Sheet

The company has $252.48 million in cash and $210.89 million in debt, giving a net cash position of $41.60 million or $0.79 per share.

Cash & Cash Equivalents 252.48M
Total Debt 210.89M
Net Cash 41.60M
Net Cash Per Share $0.79
Equity / Book Value 11.57M
Book Value Per Share 0.22
Working Capital 202.67M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$216.42 million and capital expenditures -$5.69 million, giving a free cash flow of -$222.10 million.

Operating Cash Flow -216.42M
Capital Expenditures -5.69M
Free Cash Flow -222.10M
FCF Per Share -$4.07
Full Cash Flow Statement

Margins

Gross margin is 100.00%, with operating and profit margins of -13,980.93% and -15,207.80%.

Gross Margin 100.00%
Operating Margin -13,980.93%
Pretax Margin -15,207.63%
Profit Margin -15,207.80%
EBITDA Margin -13,218.51%
EBIT Margin -13,390.07%
FCF Margin -12,456.76%

Dividends & Yields

Inhibrx does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -25.20%
Shareholder Yield -25.20%
Earnings Yield -15.16%
FCF Yield -12.41%

Analyst Forecast

Price Target n/a
Price Target Difference n/a
Analyst Consensus Hold
Analyst Count 1
Revenue Growth Forecast (5Y) 187.52%
EPS Growth Forecast (5Y) -24.52%
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Inhibrx has an Altman Z-Score of -1.37 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -1.37
Piotroski F-Score 2